surgical procedures, but also the administration of medicines to control lipids, blood pressure, antidepressants and even hypoglycemia, and even then those expenditures does not consider the indirect expenses such as transportation and escort the patient to the hospital and absence from work.

PCV63 ESTIMATING THE COSTS OF CARDIAC REHABILITATION PROGRAMS IN HEART FAILURE (HF) IN COLOMBIA: CONSTRUCTION BASED ON EXPERT CONSENSUS
Rincón M1, Tamayo D1, Rojas M2, Dennis R1, Brophy J2
1Fundacion Cardioinfantil, Bogota, Colombia, 2Universidad Javeriana, Bogota, Colombia, 3McGill University, Montreal, QC, Canada
OBJECTIVES: To determine the costs and the components of an exercised-based rehabilitation program for patients with chronic systolic HF, from the point of view of the provider of the service. METHODS: Systematic review of the literature and expert consensus. Identification of components of HF rehabilitation programs, based on the literature, and Delphi rounds of experts for consensus. Only variable costs associated with the components of the program were estimated, based on the Colombian 256 agreement of 2001 (the Colombian norm that set the tariff for reimbursement for health care services) plus 23%, 30%, or 48%, to approximate the range of costs in current (2012) health care were estimated, based on the Colombian 256 agreement of 2001 (the Colombian agreement of 2001). After the second round, over 80% agreement was obtained for the remaining three components, and an additional component was identified. After the third round, consensus was obtained for a program of 36 rehabilitation sessions and 19 components. With the base-case scenario agreement 256 plus 30%, the cost per session of the program was inversely proportional to the number of patients in each session: COL $96,903 for one patient, and COL $11,623 for 15 patients. For a program with 10 patients per session, the costs of a program may range from COL $656,554 to COL $471,130, depending on the type of agreement. Agreement is critical to unify criteria on the components of a rehabilitation program that is both effective and safe for patients with HF. From the point of view of health care cost payers, the variable costs associated with implementation are sensitive to the number of patients per session. This study should set the basis for the estimation of the cost-effectiveness of rehabilitation programs in heart failure.

PCV64 ECONOMIC EVALUATION OF INFLUENZA VACCINATION IN PREVENTING HOSPITALIZATION IN CARDIOVASCULAR DISEASE PATIENTS
Pessaux P1, Molter J1
1Centers for Disease and Prevention, Atlanta, GA, USA, 2Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: Although the Advisory Committee for Immunization Practices (ACIP) and other organizations recommend annual influenza vaccination for cardiovascular disease patients (CVD), the vaccination rate is low in this risk group. Economic assessment of vaccination will aid public officials plan cardiovascular disease prevention programs. METHODS: We estimated using a Monte Carlo (probabilistic) spreadsheet-based decision tree, the cost-effectiveness of vaccination to prevent hospitalization and death in all 27.1 million CVD patients in the US. We then estimated the benefit-cost ratios (BCRs) associated with hospitalization or death averted by influenza vaccination. We estimated the rates by age, sex, and CVD category. We estimated the cost of hospitalization and death. Finally, we estimated the incremental benefit-cost ratios (BCRs) and the incremental cost-effectiveness ratios (ICERs) by age and sex to assess if the BCRs were calculated, and the results were illustrated by incremental risk-benefit planes. To account for differential risk preferences across patients, the results were also illustrated using risk-benefit acceptability curves and net benefit curves. RESULTS: When risk was defined as having any adverse event, serious CV event, or headache, sildenafil was dominated by vardenafil (ICER=-1.00, -0.20, and -3.20, respectively). Tadalafil showed increasing risk and benefit as compared to vardenafil (ICER=0.83, 0.03, and 0.13, respectively). Tadalafil dominated sildenafil and vardenafil when balancing between the risk of flushing/dyspepsia and the drug efficacy. CONCLUSIONS: Based on patients’ concern of various categories of adverse events and assuming negligible concern over medical costs, vardenafil or tadalafil may be preferred over sildenafil.

PCV65 ESTIMATING COSTS SAVINGS FROM A CME ACTIVITY TO PREVENT BLEEDING-RELATED COMPLICATIONS AND TRANSFUSION
Ravn D, Ravn V, Lowney R, Ferraris VA
1CMoney, West Hartford, CT, USA, 2University of Colorado, Aurora, CO, USA, 3University of Kentucky, Lexington, KY, USA
OBJECTIVES: In 2011, investments in continuing medical education (CME) exceeded $2 billion. Few studies report the economic impact of CME activities. Greater understanding of the economic value of CME assists stakeholders and health care cost payers in resource allocation. It is not feasible to obtain patient-level data after each CME activity. We developed a model to estimate the potential health care cost savings associated with CME activity outcomes. METHODS: We evaluated data from a certified CME symposium for surgeons that focused on the Society of Thoracic Surgeons guidelines. The activity promoted prevention of bleeding-related complications (BRCs). We estimated the potential savings of averted BRCs from the provider perspective. RESULTS: The incremental benefit-cost ratio (BCR) was 3 in 10 participants preventing one BRC in 2% of operations over 1 year. Probabilistic sensitivity analysis (PSA) using second-order Monte Carlo simulations was used to model parameter uncertainty. Results were standardized to 2012 US$ using the medical care component of the Consumer Price Index. RESULTS: 93.8% of participants (n=133) reported CTC, a validated measure of behavior change. For BRCs, the savings for the base case was $2,974,497. PSA estimated the mean savings as $2,959,117 (95% CI, $1,135,992–$5,566,487). CONCLUSIONS: Plausible economic estimates suggest that CME-related activities favorably impacting clinical practice yield substantial cost savings. Model prediction of averted costs associated with CME allows estimating the economic impact on surgical outcomes in the absence of patient-level outcomes data related to CME activities.

PCV66 EVALUATION OF ECONOMIC AND MEDICAL CONSEQUENCES OF THE ROTARY LEFT VENTRICULAR ASSIST DEVICE WITH A DISCHARGE AT HOME IN FRANCE
Molinier L1, Ferlicq L2, Duthie JP3, Duveaux D4, Flecher E4, Leprince P5, Massetti M6, Parienti JJ7, Sabatier R3, Trochu JN4, Khayat A2
1INSERM-University Hospital of Toulouse, Toulouse, France, 2University hospital of Toulouse, Toulouse, France, 3University Hospital of Caen, Caen, France, 4University Hospital of Nantes, Nantes, France, 5University Hospital of Rennes, Rennes, France, 6Hospital of La pité Salpêtrière, Paris, France
OBJECTIVES: Advanced heart failure (HF) is a leading cause of death in developed countries with a one-year mortality rate estimated at 40% after the first hospitalization. In France, HF affects 150 000 persons with annual costs of up to 1.6 billion euros. Cardiac transplantation is the most effective treatment. However, because of a limited donor organ supply, innovative techniques as left rotary ventricular assist devices (LVADs) are developed as bridge to transplantation for over 10 years. The aim of this study is to assess the medical and economic consequences of LVAD in adults advanced HF in France. METHODS: Between April 2008 and November 2011, 55 patients were included in this study in 14 French hospitals and were followed during one year after implantation. The primary medical outcome was the discharge at home and secondary medical outcome was the final situation of patient. This prospective economic analysis adopted the health care payer’s perspective and took into account direct medical and indirect costs. RESULTS: This intermediate analysis included 21 patients. LVAD used are HeartMate II (n=12), Jarvik 2000 (n=8) and Ventritess (n=1). On the 21 patients, 15 were discharged at home spending an average of 265 days (8.7 months) at home. During the follow-up period, 4 patients were transplant, 6 patients died, and 1 patient was still on device at home. The mean total cost per implanted patient was €161,843 (±36,533). The device and initial hospitalization are the most important costs and represent respectively 58% and 30% of the total cost. One-day spent at home costs in average €59 (±15,900/ hospitalization averted, and €76,588 (± CS to €534,658)/ premature death averted. The base case BCR is 0.52. A 10% increase in vaccination rate costing $412 million ($7.2 million) would result in hospitalization savings of $288 million ($5165 million) (BCR=0.68). Achieving healthy 2020 goal would cost $257 million ($6.45 million) and result in $216 million ($4.14 billion) hospitalization savings (BCR=0.84). CONCLUSIONS: Increasing vaccination coverage rate among CVD patients will avert hospitalization and most likely deaths, but with variability in economic impact.

PCV67 QUANTITATIVE RISK-BENEFIT ANALYSIS OF ORAL PHOSPHODIESTERASE TYPE 5 INHIBITORS ON ERECTILE DYSFUNCTION TREATMENT
Hsu JC1, Tsung TP2
1National Taiwan Kang University, Taipei, Taiwan, 2University of Arizona, Tucson, AZ, USA
OBJECTIVES: Erectile dysfunction is a common male sexual disorder worldwide. Three oral medications –ildenafil, vardenafil, and tadalafl – have been used to treat erectile dysfunction. This study aims: to conduct a meta-analysis of the therapeutic risks and benefits of the three medications to assist decision making of prescribing from the perspective of both physicians and patients. METHODS: A decision model was created to compare the risk-benefit of the aforementioned medications. A decision tree model was developed in R software and a Monte Carlo simulation was performed to estimate the total cost of adverse event (i.e., risk; categories included: any adverse event, serious cardiovascular (CV) events, headache, flushing, and dyspepsia) and effectiveness (defined as proportion of patients with improved erections). The incremental risk-benefit ratios (ICBRs) were calculated, and the results were illustrated by incremental risk-benefit planes. To account for differential risk preferences across patients, the results were also illustrated using risk-benefit acceptability curves and net benefit curves. RESULTS: When risk was defined as having any adverse event, serious CV event, or headache, sildenafil was dominated by vardenafil (ICBR=-1.00, -0.20, and -3.20, respectively). Tadalafil showed increasing risk and benefit as compared to vardenafil (ICBR=0.83, 0.03, and 0.13, respectively). Tadalafil dominated sildenafil and vardenafil when balancing between the risk of flushing/dyspepsia and the drug efficacy. CONCLUSIONS: Based on patients’ concern of various categories of adverse events and assuming negligible concern over medical costs, vardenafil or tadalafl may be preferred over sildenafil.

PCV68 ECONOMIC COMPARISON OF HEMOSTATIC AGENTS IN CARDIAC SURGERY
Sugerman B1, Tackett S2, Li McLeod J3, Kreweval H, Alvarez P1, Nasso G1
1United BioSource Corporation, Lexington, MA, USA, 2Baxter Healthcare, Westlake Village, CA, USA, 3Baxter, Westlake Village, CA, USA, 4Anthea Hospital, JVM Care & Research, Bari, Italy